These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 7862953)

  • 1. Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats.
    Poncelet M; Souilhac J; Gueudet C; Terranova JP; Gully D; Le Fur G; Soubrié P
    Psychopharmacology (Berl); 1994 Oct; 116(2):237-41. PubMed ID: 7862953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat.
    Stoessl AJ; James KA; Napier BJ
    Neuropharmacology; 1997 Jan; 36(1):93-9. PubMed ID: 9144645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical neuroleptic-like behavioral effects of neurotensin.
    Jolicoeur FB; Gagné MA; Rivest R; Drumheller A; St-Pierre S
    Brain Res Bull; 1993; 32(5):487-91. PubMed ID: 8106129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine-induced penile erection and yawning: site of action in brain.
    Melis MR; Argiolas A; Gessa GL
    Brain Res; 1987 Jul; 415(1):98-104. PubMed ID: 3497688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission.
    Steinberg R; Brun P; Fournier M; Souilhac J; Rodier D; Mons G; Terranova JP; Le Fur G; Soubrié P
    Neuroscience; 1994 Apr; 59(4):921-9. PubMed ID: 8058127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy.
    Chartoff EH; Szczypka MS; Palmiter RD; Dorsa DM
    Brain Res; 2004 Oct; 1022(1-2):71-80. PubMed ID: 15353215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.
    Zarrindast MR; Poursoltan M
    Br J Pharmacol; 1989 Apr; 96(4):843-8. PubMed ID: 2663110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of dihydropyridine compounds in behavioural tests of dopaminergic activity.
    Bourson A; Gower AJ; Mir AK; Moser PC
    Br J Pharmacol; 1989 Dec; 98(4):1312-8. PubMed ID: 2482105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the D1 receptor agonist SKF 38393 on some behavioural effects of apomorphine in rats.
    Zarkovsky AM; Cereska KS
    Naunyn Schmiedebergs Arch Pharmacol; 1989 Apr; 339(4):383-6. PubMed ID: 2567965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation by sudden darkness of apomorphine-induced behavioral responses.
    Nasello AG; Sassatani AS; Ferreira FS; Felicio LF; Tieppo CA
    Physiol Behav; 2003 Apr; 78(4-5):521-8. PubMed ID: 12782204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats.
    da Silva GE; Fernandes MS; Takahashi RN
    Neurosci Lett; 2003 Sep; 349(1):49-52. PubMed ID: 12946584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist.
    Ferrari F; Pelloni F; Giuliani D
    Psychopharmacology (Berl); 1993; 113(2):172-6. PubMed ID: 7855178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioural responses in rats.
    Rimondini R; Ferré S; Giménez-Llort L; Ogren SO; Fuxe K
    Eur J Pharmacol; 1998 Apr; 347(2-3):153-8. PubMed ID: 9653875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of apomorphine-induced yawning and penile erection by neurotensin.
    Nouel D; Costentin J
    Peptides; 1991; 12(4):755-9. PubMed ID: 1788138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural effects induced in rats and chicks by D2 dopamine agonists.
    Ferrari F; Giuliani D
    Physiol Behav; 1993 Oct; 54(4):695-700. PubMed ID: 7902587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats.
    Ushijima I; Mizuki Y; Yamada M
    Psychopharmacology (Berl); 1988; 95(1):29-33. PubMed ID: 2898789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic blockade of neurotensin receptors strongly reduces sensitized, but not acute, behavioral response to D-amphetamine.
    Panayi F; Dorso E; Lambás-Señas L; Renaud B; Scarna H; Bérod A
    Neuropsychopharmacology; 2002 Jan; 26(1):64-74. PubMed ID: 11751033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropharmacological profile of non-peptide neurotensin antagonists.
    Gully D; Jeanjean F; Poncelet M; Steinberg R; Soubrié P; Le Fur G; Maffrand JP
    Fundam Clin Pharmacol; 1995; 9(6):513-21. PubMed ID: 8808171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of age on behavioral responses to dopamine agonists in the rat.
    Ushijima I; Mizuki Y; Soeda K; Kishimoto O; Hara T; Yamada M
    Eur J Pharmacol; 1987 Jun; 138(1):101-6. PubMed ID: 2887433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD; Harting J; Minck KO
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.